118 related articles for article (PubMed ID: 3144539)
1. Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.
Shah PM; Sammann A; Schäfer V; Seczendi M; Knothe H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():209-13. PubMed ID: 3144539
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
[TBL] [Abstract][Full Text] [Related]
3. Renal tolerance of fleroxacin in healthy volunteers.
Mondorf AW; Buch A; Steinbacher G; Rüdel C; Falkenberg FW
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():179-89. PubMed ID: 2904925
[TBL] [Abstract][Full Text] [Related]
4. Single and multiple dose pharmacokinetics of fleroxacin.
Weidekamm E; Portmann R; Partos C; Dell D
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures.
Bauernfeind A; Eberlein E; Hörl G
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():81-9. PubMed ID: 3144553
[TBL] [Abstract][Full Text] [Related]
6. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
[TBL] [Abstract][Full Text] [Related]
8. Altered disposition of fleroxacin in patients with cystic fibrosis.
Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of fleroxacin.
Georgopoulos A; Breyer S; Georgopoulos M; Mailer H; Graninger W
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():25-9. PubMed ID: 3144544
[TBL] [Abstract][Full Text] [Related]
10. Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.
Parent M; St-Laurent M; LeBel M
Antimicrob Agents Chemother; 1990 Jun; 34(6):1249-53. PubMed ID: 2118328
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
Sorgel F; Metz R; Naber K; Seelmann R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral ciprofloxacin on the faecal flora of healthy volunteers.
Holt HA; Lewis DA; White LO; Bastable SY; Reeves DS
Eur J Clin Microbiol; 1986 Apr; 5(2):201-5. PubMed ID: 2941281
[TBL] [Abstract][Full Text] [Related]
13. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.
Aoyama H; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():99-114. PubMed ID: 2849604
[TBL] [Abstract][Full Text] [Related]
14. Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli KL 16.
Lewin CS; Amyes SG
J Med Microbiol; 1990 Jun; 32(2):83-6. PubMed ID: 1693968
[TBL] [Abstract][Full Text] [Related]
15. Effect of sub-minimal inhibitory concentrations of ciprofloxacin and fleroxacin on the bacterial capsular antigen and opsonophagocytosis by human polymorphonuclear leukocytes.
Keller N; Raponi G; Hoepelman IM; Overbeek BP; Rozenberg-Arska M; Verhoef J
Zentralbl Bakteriol; 1991 Jan; 274(4):519-26. PubMed ID: 1907453
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic study of lomefloxacin and its effect on the faecal flora of volunteers.
Leigh DA; Harris C; Tait S; Walsh B; Hancock P
J Antimicrob Chemother; 1991 May; 27(5):655-62. PubMed ID: 1885423
[TBL] [Abstract][Full Text] [Related]
18. Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.
Paganoni R; Herzog C; Braunsteiner A; Hohl P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():3-17. PubMed ID: 3144545
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies of fleroxacin and ofloxacin in experimental pyelonephritis.
Ritzerfeld W
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():119-22. PubMed ID: 3144529
[TBL] [Abstract][Full Text] [Related]
20. An in vitro investigation of the intraphagocytic bioactivity of difloxacin, ciprofloxacin, pefloxacin and fleroxacin.
van Rensburg CE; Joone G; Anderson R
Chemotherapy; 1989; 35(4):273-7. PubMed ID: 2504545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
